RT Journal Article
SR Electronic
T1 SARS-CoV-2 seroprevalence in a rural and urban community household cohort in South Africa, after the third wave, April-November 2021
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.10.22270772
DO 10.1101/2022.02.10.22270772
A1 Kleynhans, Jackie
A1 Tempia, Stefano
A1 Wolter, Nicole
A1 Gottberg, Anne von
A1 Bhiman, Jinal N.
A1 Buys, Amelia
A1 Moyes, Jocelyn
A1 McMorrow, Meredith L.
A1 Kahn, Kathleen
A1 Gómez-Olivé, F. Xavier
A1 Tollman, Stephen
A1 Martinson, Neil A.
A1 Wafawanaka, Floidy
A1 Lebina, Limakatso
A1 Toit, Jacques du
A1 Jassat, Waasila
A1 Neti, Mzimasi
A1 Brauer, Marieke
A1 Cohen, Cheryl
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/02/15/2022.02.10.22270772.abstract
AB By November 2021, after the third SARS-CoV-2 wave in South Africa, seroprevalence was 60% (95%CrI 56%-64%) in a rural and 70% (95%CrI 56%-64%) in an urban community; highest in individuals aged 13-18 years. High seroprevalence prior to Omicron emergence may have contributed to reduced severity observed in the 4th wave.Article Summary Line In South Africa, after a third wave of SARS-CoV-2 infections, seroprevalence was 60% in a rural and 70% in an urban community, with case-to-infection, - hospitalization and -fatality ratios similar to the second wave.Competing Interest StatementCheryl Cohen reports receiving grant funds from US-Centers for Disease Control and Prevention, Wellcome Trust and South African Medical Research Council. Nicole Wolter and Anne von Gottberg report receiving grant funds from Sanofi and Gates Foundation. All other authors have no competing/conflict of interest.Funding StatementThis work was supported by the National Institute for Communicable Diseases of the National Health Laboratory Service and the US Centers for Disease Control and Prevention (cooperative agreement number 6U01IP001048-04-02 awarded to C Cohen). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the University of the Witwatersrand Human Research Ethics Committee (Reference 150808) and the US Centers for Disease Control and Prevention relied on local clearance (IRB #6840).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe investigators welcome enquiries about possible collaborations and requests for access to the dataset. Data will be shared after approval of a proposal and with a signed data access agreement. Investigators interested in more details about this study, or in accessing these resources, should contact the corresponding author.